Pneumococcal infection in the whole world and Ukraine in particular. Possibilities of its prevention

Abstract

These days pneumococcal infection is an actual problem due to its wide distribution, severe clinical forms, growth of pneumococcal resistance. It determines high mortality from this pathology. It forms the need to prevention pneumococcal infection, especially in the risk groups of severe course of the disease. According to WHO, vaccination is the unique method substantially influencing pneumococcal infection morbidity and consequently, decreasing antibiotic usage for its treatment. 13-valent pneumococcal polysaccharide conjugate absorbed vaccine provides the new approach to pneumococcal diseases prevention including non-hospitalized pneumonia in adults. PCV13 vaccination is recommended to adults after 50 y.o., especially with the high risks of invasive pneumococcal disease development (age 65 years and more, persons with the immunodeficiency, chronic concomitant diseases).